Randomized phase III trial of trastuzumab + alpelisib +/- fulvestrant versus trastuzumab + chemotherapy in previously treated patients with HER2+ advanced breast cancer with PIK3CA mutation. “ALPHABET STUDIO”
INDEPENDENT CLINICAL TRIAL
Clinical trial information
- Promoter: SPANISH BREAST CANCER RESEARCH GROUP FOUNDATION
- Phase: III
- Execution start: 14/09/2021
- End of execution: 30/05/2026
- IP: ISABEL BLANCAS LOPEZ-BARAJAS